Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Modality
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Modality outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Continuous Renal Replacement Therapy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Continuous Renal Replacement Therapy Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Continuous Renal Replacement Therapy Market: Product Estimates & Trend Analysis
4.1. Continuous Renal Replacement Therapy Market: Key Takeaways
4.2. Continuous Renal Replacement Therapy Market: Movement & Market Share Analysis, 2022 & 2030
4.3. System
4.3.1. System market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Consumables
4.4.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Continuous Renal Replacement Therapy Market: Modality Class Estimates & Trend Analysis
5.1. Continuous Renal Replacement Therapy Market: Key Takeaways
5.2. Continuous Renal Replacement Therapy Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Slow Continuous Ultra-Filtration (SCUF)
5.3.1. Slow continuous ultra-filtration market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Continuous Venovenous Hemofiltration (CVVH)
5.4.1. Continuous venovenous hemofiltration (CVVH) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Continuous Venovenous Hemodialysis (CVVHD)
5.5.1. Continuous venovenous hemodialysis (CVVHD) market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Continuous Venovenous Hemodiafiltration (CVVHDF)
5.6.1. Continuous venovenous hemodiafiltration (CVVHDF) market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Continuous Renal Replacement Therapy Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Continuous Renal Replacement Therapy Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. U.K.
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Participants
7.2. Market Participant Categorization
7.2.1. B. BRAUN MELSUNGEN AG
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. BAXTER INTERNATIONAL, INC.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. FRESENIUS MEDICAL CARE AG & CO. KGAA
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. ASAHI KASEI CORPORATION
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. NIPRO CORPORATION
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. TORAY MEDICAL CO., LTD.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. NXSTAGE MEDICAL, INC
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. MEDTRONIC PLC
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/